State Street Health Care ETF Tops Invesco Pharma on Cost and Size

The article contrasts two healthcare ETFs: Invesco’s PJP (expense ratio 0.57%) concentrates in 29 pharma companies, while State Street’s XLV is a broader healthcare basket with a much lower 0.08% expense ratio and higher dividend yield (1.6% vs 0.9%). Over the prior year (as of Jun 30, 2026), PJP delivered stronger total return (49.9%) than XLV (19.8%), but XLV’s larger AUM ($40.9B vs $353.9M) implies higher liquidity and potentially tighter trading spreads. Net: investors choose between PJP’s higher returns with higher fees and XLV’s diversification, lower costs, and better income profile.

Analysis

This is mostly an implementation story, not a sector signal. For institutional capital, XLV is the cleaner wrapper: lower fee drag, tighter spreads, and enough AUM to absorb size without forcing market-impact leakage. That matters most in a sideways-to-slightly-defensive tape, where the annualized expense gap compounds into a real return differential and passive flows tend to reward the most liquid vehicle first.

The more interesting issue is concentration risk inside PJP. Its recent outperformance is likely being driven by a narrow set of pharma winners, so the ETF behaves more like a levered single-theme basket than a diversified healthcare allocation. If LLY momentum cools, or if drug-pricing/regulatory headlines re-rate the pharma complex, PJP should give back faster than XLV because there is less cushion from non-pharma healthcare names. The market may be overpaying for trailing returns while underestimating how quickly that can mean-revert when leadership broadens.

Contrarian view: the recent preference for PJP may actually be the better trade if investors are still chasing obesity/drug-innovation beta, but that is a crowded and fragile premise. The thesis is falsified if LLY keeps compounding earnings beats and fund flows stay concentrated in pharma for another 1-2 quarters; in that case PJP’s higher tracking error becomes a feature, not a bug. Absent that, XLV is the more durable six- to eighteen-month holding, especially for allocators who value liquidity and lower implementation cost over maximal thematic upside.

Key Decisions for Investors

• Prefer XLV over PJP for core healthcare exposure on any 1-3 month pullback; the cleaner liquidity/fee profile should outperform on a net-of-cost basis even if gross sector returns are similar.